Charles River Laboratories International (CRL) Liabilities and Shareholders Equity (2009 - 2025)

Charles River Laboratories International's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $7.1 billion for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 5.22% year-over-year to $7.1 billion; the TTM figure through Dec 2025 stood at $29.8 billion (down 5.82% YoY), while the FY2025 annual figure was $7.1 billion, down 5.22% from the prior year.
• Liabilities and Shareholders Equity was $7.1 billion for Q4 2025 at Charles River Laboratories International, down from $7.5 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $8.2 billion in Q4 2023 to a low of $5.8 billion in Q1 2021.
• Historically, Liabilities and Shareholders Equity has averaged $7.4 billion across 5 years, with a median of $7.5 billion in 2022.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity gained 28.23% in 2021, then slipped 8.13% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $7.0 billion in 2021, then gained by 8.24% to $7.6 billion in 2022, then increased by 7.79% to $8.2 billion in 2023, then decreased by 8.13% to $7.5 billion in 2024, then slipped by 5.22% to $7.1 billion in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $7.1 billion (Q4 2025), $7.5 billion (Q3 2025), and $7.6 billion (Q2 2025), per Business Quant data.